CLL Prognostication/Risk Stratification Gene Panel near me in Bhopal

The CLL Prognostication/Risk Stratification Gene Panel is a Next-Generation Sequencing (NGS)–based molecular test performed on EDTA whole blood samples. It analyzes key genes and mutations linked with the development and behavior of Chronic Lymphocytic Leukemia (CLL), a cancer of the blood and bone marrow that affects white blood cells.

CLL is a heterogeneous disease, meaning it behaves differently in every patient. Some cases progress slowly and require only monitoring, while others are more aggressive and need early intervention. This gene panel helps doctors assess an individual’s risk level and make informed clinical decisions.

The test evaluates mutations in important hotspot, full, and fusion genes associated with CLL and other hematological malignancies:

• Hotspot genes: ABL1, FLT3, JAK2, MYD88, SF3B1
• Full genes: SH2B3, TP53
• Gene fusions: FGFR1, FGFR2, PDGFRA, PDGFRB

By detecting these gene mutations, the test helps doctors stratify patients into risk categories (low, intermediate, or high risk) and decide on the most suitable treatment approach, whether active monitoring, targeted therapy, or clinical trial enrollment.

Doctors may recommend this test for individuals with newly diagnosed CLL, persistent or relapsed disease, or those who show clinical signs of disease progression such as rapid lymphocyte doubling, cytopenias, or organ enlargement.

For this test, it is important to submit the clinical history, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled.

Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for a proper understanding of the test results.